FNY Investment Advisers’s Usana Health Sciences USNA Stock Holding History

FNY Investment Advisers’s Portfolio USNA Stock Details USNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-7,000	Closed	-$549K	–	821
2019 Q4	$549K	Buy	+7,000	New	+$516K	0.17%	92
2018 Q4	–	Sell	-26	Closed	-$3K	–	1034
2018 Q3	$3K	Hold	26	–	–	﹤0.01%	690
2018 Q2	$2K	Buy	+26	New	+$2.84K	﹤0.01%	849

Other funds holding USNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

FNY Investment Advisers's USNA Position: Q1 2020 in Review

FNY Investment Advisers sold out of Usana Health Sciences (USNA) in Q1 2020, closing a stake of 7,000 shares — an estimated $549K sold.

FNY Investment Advisers first reported a position in USNA in Q2 2018 and held it in 3 quarters. The position peaked at $549K in Q4 2019. 169 funds tracked by Wall St. Rank hold USNA as of Q1 2020.

FNY Investment Advisers reported no remaining Usana Health Sciences position as of Q1 2020 after selling out during the quarter.
FNY Investment Advisers sold 7,000 Usana Health Sciences shares in Q1 2020, an estimated $549K.
FNY Investment Advisers first reported a position in Usana Health Sciences in Q2 2018 and held it in 3 quarters.
FNY Investment Advisers's Usana Health Sciences position peaked at $549K in Q4 2019.
169 funds tracked by Wall St. Rank held Usana Health Sciences as of Q1 2020.

Based on FNY Investment Advisers's 13F filing for Q1 2020, filed 9 Apr 2020.